Wyeth/Progenics Aim To Preempt Review Concerns To Expand Relistor Use
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With FDA approval in hand, Wyeth and Progenics are building the Relistor database before the companies move to expand the opioid-induced constipation drug's use beyond its relatively limited initial population of patients with advanced illness